Fig. 1From: Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspectiveModel structure. *The efficacy parameter depends on the criteria chosen—PsARC alone (for base case analysis), PASI, or a combination of PsARC and PASI (for alternative scenario analysis). Tx, treatmentBack to article page